Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

No classification is warranted for the acute toxicity. 

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1986-09-04 to 1986-10-09
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Scientifically well performed study
Qualifier:
according to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
no
GLP compliance:
no
Test type:
standard acute method
Limit test:
no
Species:
rat
Strain:
Wistar
Sex:
male/female
Route of administration:
oral: gavage
Vehicle:
other: Sesame oil
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 20% in 2000 mg/kg Group; 5% in 500 mg/kg Group
- Amount of vehicle (if gavage): 10 ml /kg body weight


Doses:
2000 mg/kg (male); 500, 2000 mg/kg (female)
No. of animals per sex per dose:
5
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Daily during the study
- Necropsy of survivors performed: yes
- Other examinations performed:
clinical signs During the first 10, 30, 60 minutes, 2, 4 and 6 hours after the administration. Twice daily during days 1-14
body weight: On test day 0, 7 and 14 (after the administration)
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
act. ingr.
Mortality:
On test day 8, one female animal was found dead in 2000 mg/kg group (20% mortality)
Clinical signs:
other: One female that was found dead on day 8 exhibited clinical signs on day 6 and 7. No clinical sign was found in other animals during the study.
Gross pathology:
The animal died on day 8 was found to have light pink colored lung.

Table: Body weight development

Sex/dose level

Initial body weight

 

Body weight gain: day 0-7

Body weight gain: day 7-14

Males/2000 mg/kg bw

176

55

40

180

47

44

175

50

48

178

63

52

186

52

47

179 ± 4 (n=5)

53 ± 6 (n=5)

46 ± 4 (n=5)

Females/2000 mg/kg bw

175

16

9

172

28

22

180

18

7

180

17

15

178

-11

*

177 ± 3 (n=5)

14 ± 15 (n=5)

13 ± 7 (n=4)

Females/500 mg/kg bw

171

34

11

 

173

26

11

 

170

27

7

 

179

31

15

 

173

37

8

 

173 ± 3 (n=5)

31 ± 5 (n=5)

10 ± 3 (n=5)

*Found dead

Interpretation of results:
study cannot be used for classification
Remarks:
Migrated information
Conclusions:
The median lethal dose of Dodigen 1481 after single oral administration to rats, observed over a period of 14 days is:
LD50 (Rat): greater than 2000 mg/kg body weight
Executive summary:

NA-DETA was given to rats per gavage at dose levels of 2000 mg/kg bw for males and 2000 and 500 mg/kg bw for females.

At 2000 mg/kg bw, one female out of five died 7 days after treatment and exhibited body weight reduction prior to death. The survived animals exhibted transiently reduced body weight gain.

No effect was found for males upon application of 2000 mg/kg bw and for females upon application of 500 mg/kg bw.

No classification is warranted for the acute oral toxicity of NA-DETA

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
discriminating dose
Value:
2 000 mg/kg bw
Quality of whole database:
One valid acute oral toxicity study

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available
Quality of whole database:
No study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2012-06-08 to 2012-11-02
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.3 (Acute Toxicity (Dermal))
Deviations:
no
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.1200 (Acute Dermal Toxicity)
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Remarks:
(Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
Test type:
standard acute method
Limit test:
yes
Species:
rat
Strain:
Wistar
Sex:
male/female
Details on test animals or test system and environmental conditions:
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3 °C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. XX)
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot no. XX)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions
Type of coverage:
semiocclusive
Vehicle:
unchanged (no vehicle)
Details on dermal exposure:
Preparation of the Animals:
The animals were marked for individual identification by tail painting.
Approximately 24 hours before the test, the fur was removed from the dorsal area of the trunk using an electric clipper. Care was taken to avoid abrading the skin, and only animals with healthy intact skin were used.
No less than 10% of the body surface was cleared for the application.
Prior to the application a detailed clinical observation was made of all animals.
Application:
The test item was applied at a single dose, uniformly over an area which was approximately 10% of the total body surface.
The test item was held in contact with the skin by a dressing throughout a 24-hour period. The dressing consisted of a gauze-dressing and non-irritating tape and was fixed with an additional dressing in a suitable manner.
Duration of exposure:
The test item was held in contact with the skin throughout a 24-hour period. At the end of the exposure period the residual test item was removed.
Doses:
The test item was applied at a single dose of 2000 mg/kg body weight to each animal.
No. of animals per sex per dose:
5 male and 5 female
Control animals:
not required
Details on study design:
Observation period:
All animals were observed for 14 days after dosing

Weight Assessment:
The animals were weighed on day 1 (prior to the application) and on days 8 and 15.

Clinical Examination:
careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given
during the first 4 hours post-dose). As soon as symptoms were noticed they were recorded. Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded.
Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory, autonomic and central
nervous systems and somatomotor activity and behaviour pattern were examined. Attention was directed to observations of tremors, convulsions,
salivation, diarrhoea, lethargy, sleep and coma.

Pathology:
At the end of the observation period the surviving animals were sacrificed with an overdosage of pentobarbital injected intraperitoneally (Narcoren®, Merial) at the dosage of approximately 8 mL/kg bw. All animals were subjected to gross necropsy. All gross pathological changes were recorded and in case of findings the tissues were preserved for a possible histopathological evaluation. The preserved tissues of which no histopathological
evaluation was made will be discarded 3 months after the release of the final report unless otherwise agreed upon with the sponsor.

Evaluation of Results:
Individual reactions of each animal were recorded at each time of observation.
Toxic response data were recorded by sex and dose level.
Nature, severity and duration of clinical observations were described.
The body weight changes were summarised in a tabular form.
Necropsy findings were described.

Statistics:
According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the
results is not regarded as necessary.
Sex:
male/female
Dose descriptor:
LD0
Effect level:
2 000 mg/kg bw
Based on:
test mat.
Mortality:
No mortality was observed
Clinical signs:
other: No treatment-related effects were observed.
Gross pathology:
No treatment-related effects were observed.
Other findings:
Erythema grade 1 and 2 were observed in 5 of 5 male and 5 of 5 female animals. Oedema grade 1 was observed in 3 of 5 male and 4 of 5 female
animals. Oedema grade 2 was observed in 1 of 5 female animals. Eschar was observed in 5 of 5 male and 5 of 5 female animals. Wound was
observed in 2 of 5 male and 3 of 5 female animals. Necrosis was observed in 1 of 5 female animals.
All signs of irritation were not fully reversible within the observation period.

Table Clinical Signs of Systemic Toxicity – Individual Data - Males:

Animal
No. / Sex / Dose

Time of
Observation (Post-Dose)

Observations

(for Signs of Dermal Irritation, see Table 5)

21/ male /
2000 mg/kg bw

during the whole observation period

no signs of toxicity

22/ male /
2000 mg/kg bw

during the whole observation period

no signs of toxicity

23/ male /
2000 mg/kg bw

during the whole observation period

no signs of toxicity

24/ male /
2000 mg/kg bw

during the whole observation period

no signs of toxicity

25/ male /
2000 mg/kg bw

during the whole observation period

no signs of toxicity

min = minute(s), h = hour(s), bw = body weight

Table Clinical Signs of Systemic Toxicity – Individual Data – Females:

Animal
No. / Sex / Dose

Time of
Observation (Post-Dose)

Observations

(for Signs of Dermal Irritation, see Table 6)

26/ female / 2000 mg/kg bw

during the whole observation period

no signs of toxicity

27/ female / 2000 mg/kg bw

during the whole observation period

no signs of toxicity

28/ female / 2000 mg/kg bw

during the whole observation period

no signs of toxicity

29/ female / 2000 mg/kg bw

during the whole observation period

no signs of toxicity

30/ female / 2000 mg/kg bw

during the whole observation period

no signs of toxicity

min = minute(s), h = hour(s), bw = body weight

Table Skin Irritation – Individual Data – Males:

Day after Start of Application

Animal No. 21

Animal No. 22

Animal No. 23

Animal No. 24

Animal No. 25

E/O

Comments

E/O

Comments

E/O

Comments

E/O

Comments

E/O

Comments

day 2

2/0

nsf

1/0

nsf

2/1

nsf

2/1

nsf

2/1

nsf

day 3

2/0

nsf

2/0

nsf

2/1

nsf

2/1

nsf

2/1

nsf

day 4

2/0

nsf

2/0

nsf

2/1

nsf

2/1

nsf

2/1

nsf

day 5

2/0

nsf

2/0

nsf

2/1

nsf

2/1

nsf

2/1

Es

day 6

2/0

Es

2/0

Es

2/0

Es

2/0

Es, W(10)

2/0

Es, W(15)

day 7

2/0

Es

2/0

Es

2/0

Es

2/0

Es, W(10)

2/0

Es, W(10)

day 8

1/0

Es

2/0

Es

2/0

Es

1/0

Es

1/0

Es

day 9

1/0

Es

2/0

Es

2/0

Es

1/0

Es

1/0

Es

day 10

1/0

Es

1/0

Es

2/0

Es

1/0

Es

1/0

Es

day 11

1/0

Es

1/0

Es

2/0

Es

1/0

Es

1/0

Es

day 12

1/0

Es

1/0

Es

2/0

Es

1/0

Es

1/0

Es

day 13

1/0

Es

0/0

Es

1/0

Es

1/0

Es

1/0

Es

day 14

1/0

Es

0/0

Es

1/0

Es

1/0

Es

1/0

Es

day 15

1/0

Es

0/0

Es

1/0

Es

1/0

Es

1/0

Es

 

Comments:

E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2)

Es = eschar; W (Ømm) = wound; nsf = no specific findings

 

Table Skin Irritation – Individual Data – Females:

Day after Start of Application

Animal No. 26

Animal No. 27

Animal No. 28

Animal No. 29

Animal No. 30

E/O

Comments

E/O

Comments

E/O

Comments

E/O

Comments

E/O

Comments

day 2

2/0

nsf

2/1

nsf

1/0

nsf

2/0

nsf

2/1

nsf

day 3

2/1

nsf

2/2

nsf

1/0

nsf

2/1

*

2/1

nsf

day 4

2/1

nsf

2/2

nsf

1/0

nsf

2/1

*

2/1

nsf

day 5

2/1

nsf

2/0

Es,
W (2 cm)

1/0

nsf

2/1

*

2/1

nsf

day 6

2/0

N (15)

2/1

Es,
W (2 cm)

2/0

Es,
W (15 mm)

2/1

Es, *

2/0

W (2.5 cm)

day 7

2/0

N (15)

2/1

Es,
W (2 cm)

2/0

Es,
W (15 mm)

2/1

Es, *

2/0

W (2.5 cm)

day 8

2/0

N (15)

2/0

Es

2/0

Es

2/1

Es, *

2/0

W (2.5 cm)

day 9

2/0

Es, N (15)

2/0

Es

2/0

Es

2/0

Es, *

2/0

W (2.5 cm)

day 10

2/0

Es, N (15)

2/0

Es

2/0

Es

2/0

Es, *

2/0

Es,
W (0.5 cm)

day 11

2/0

Es, N (15)

2/0

Es

2/0

Es

2/0

Es

2/0

Es,
W (0.5 cm)

day 12

2/0

Es, N (15)

2/0

Es,
W (2x4cm)

2/0

Es

2/0

Es

2/0

Es

day 13

1/0

Es

2/0

Es,
W (2x4cm)

1/0

Es

1/0

Es

1/0

Es

day 14

1/0

Es

1/0

Es,
W (1x2cm)

1/0

Es

1/0

Es

1/0

Es

day 15

1/0

Es

1/0

Es

1/0

Es

1/0

Es

1/0

Es

 

Comments:

E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2)

Es = eschar; N (Ømm) = necrosis; W (Ø) = wound; nsf = no specific findings; * = animal very nervous

 

Table Absolute Body Weights in g and Body Weight Gain in %:

Dose: 2000 mg/kg body weight

Animal No. / Sex

g
Day 1

g
Day 8

g
Day 15

%
Day 1-15

21 / male

238

243

276

16

22 / male

245

262

291

19

23 / male

232

220

249

7

24 / male

231

230

261

13

25 / male

241

238

261

8

26 / female

223

220

220

-1

27 / female

211

198

209

-1

28 / female

210

205

215

2

29 / female

221

214

220

0

30 / female

212

205

216

2

Table Macroscopic Findings - Individual Data – Males and Females:

Dose: 2000 mg/kg bw

Animal No. /
Sex

Organ

Macroscopic Findings

21 / male

-

nsf

22 / male

-

nsf

23 / male

-

nsf

24 / male

-

nsf

25 / male

liver

liver partially located in thorax

26 / female

-

nsf

27 / female

-

nsf

28 / female

-

nsf

29 / female

-

nsf

30 / female

-

nsf

nsf = no specific findings

Table LD50:

Dose (Unit)

 

Number of Animals Investigated

Number of Intercurrent Deaths

LD50

2000 mg/kg bw

5 males

0

> 2000 mg/kg bw

2000mg/kg bw

5 females

0

> 2000 mg/kg bw

bw = body weight

Interpretation of results:
study cannot be used for classification
Remarks:
Migrated information
Conclusions:
Under the conditions of the present study, single dermal application of NA-DETA to rats at a dose of 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity but signs of irritation.
The dermal LD50 was determined to be > 2000 mg/kg body weight.

Executive summary:

 The acute dermal toxicity of NA-DETA was investigated according to the Guideline OECD 402.

NA-DETA was applied dermally to rats at dose level of 2000 mg/kg body weight. No mortality, no signs of toxicity was observed.

The dermal LD50 was determined to be > 2000 mg/kg body weight.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
discriminating dose
Value:
2 000 mg/kg bw
Quality of whole database:
One valid acute dermal toxicity study.

Additional information

Justification for classification or non-classification

The LD50 for acute toxicity in rats was found to be higher than 2000 mg/kg bw for the oral and dermal exposure routes. No significant hazard can be reliably derived for inhalation routes. No classification is warranted for the acute toxicity.